NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
Zacks·2d ago
More News
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of "Moderate Buy" by Analysts
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are currently covering the firm, Marketbeat...
MarketBeat·7d ago
Fox Run Management L.L.C. Takes Position in Beam Therapeutics Inc. $BEAM
Fox Run Management L.L.C. acquired a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...
Beam Therapeutics (NASDAQ:BEAM) Shares Up 6.7% - Still a Buy...
MarketBeat·9d ago
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
Zacks·9d ago
Vestmark Advisory Solutions Inc. Has $5.49 Million Stock Holdings in Beam Therapeutics Inc. $BEAM
Vestmark Advisory Solutions Inc. raised its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 109.0% in the 2nd quarter, according to the company in its most recent Form 13F...
MarketBeat·14d ago
Cantor Fitzgerald Has Weak Forecast for BEAM FY2025 Earnings
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a...
MarketBeat·15d ago
What is HC Wainwright's Estimate for BEAM FY2025 Earnings?
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Stock analysts at HC Wainwright lowered their FY2025 earnings estimates for Beam Therapeutics in a report issued on Wednesday, November 5th. HC...
MarketBeat·15d ago
FY2025 Earnings Forecast for BEAM Issued By Leerink Partnrs
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Investment analysts at Leerink Partnrs lowered their FY2025 earnings per share estimates for shares of Beam Therapeutics in a research report...
MarketBeat·15d ago
Wall Street Zen Downgrades Beam Therapeutics (NASDAQ:BEAM) to Sell
Wall Street Zen cut shares of Beam Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...